Camlin Fine Sciences Limited

Camlin Fine Sciences Limited

83.76
INR
-2.87
(-3.31%)
-3.39EPS
431.30P/E
25.62BMarket Cap
Nov 16Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
52.83
57.22
49.73
50.82
63.13
70.75
82.01
92.68
97.42
97.58
84.96
92.28
90.38
97.88
Basic EPS, GAAP
2.98
5.64
3.64
-1.07
-2.64
0.05
2.44
4.03
4.21
3.04
-5.49
-8.03
1.46
0.31
Free Cash Flow per Basic Share
-0.99
1.85
0.46
-3.8
-3.08
-6.31
-3.88
2.65
-4.74
-5.45
4.64
-1.12
1.29
- -
Dividend per Share
0.29
0.34
0.44
0.45
- -
0.5
0.23
0.43
0.05
0.81
1.66
- -
- -
- -
Book Value per Share
9.65
13.74
18.3
20.02
29.91
29.88
32.48
49.3
46.54
50.95
50.45
47.98
54.19
- -
Tangible Book Value per Share
9.25
12.39
17.05
15.58
24.26
24.52
26.9
44.05
41.82
46.84
46.95
44.91
40.53
- -
Basic Weighted Avg Shares
96
98
98
104
112
124
124
126
144
171
169
173
189
190
Sales/Revenue/Turnover
5,087
5,583
4,893
5,284
7,101
8,781
10,179
11,712
14,044
16,713
14,362
15,978
17,112
18,617
Operating Margin (%)
11.36
13.84
15.74
2.86
-0.89
5.11
10.06
13.58
7.55
9.69
11.4
10.4
2.76
7.34
Depreciation Expense
118
162
171
218
267
290
328
443
560
625
786
737
740
755
Net Income, GAAP
287
550
358
-112
-296
6
303
510
607
521
-928
-1,390
276
59
Effective Tax Rate (%)
17.57
- -
28.39
- -
- -
81.99
48.75
37.81
35.76
50.47
9.61
- -
- -
- -
Profit Margin (%)
5.64
9.86
7.32
-2.11
-4.17
0.07
2.98
4.35
4.32
3.12
-6.46
-8.7
1.61
0.32
Working Capital
109
372
194
337
1,946
2,121
1,271
3,171
2,983
2,948
2,684
3,372
2,621
- -
LT Debt
285
281
214
513
1,102
1,936
2,212
2,817
4,047
4,224
3,499
2,934
3,370
- -
Total Equity
933
1,349
1,811
2,302
4,334
4,303
4,601
7,132
7,651
8,241
8,570
8,748
10,008
- -
Return on Invested Capital (%)
14.07
- -
9.94
- -
- -
0.98
5.69
8.88
4.98
4.87
7.82
- -
- -
- -
Return on Capital (%)
21.69
- -
13.57
- -
- -
0.37
4.74
5.41
5.96
5.58
-1.23
- -
- -
- -
Return on Common Equity (%)
36.19
48.23
22.68
-5.68
-10.16
0.16
7.83
9.74
8.72
6.65
-11.02
-15.74
2.84
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
3,831
- -
LT Borrowings
- -
3,026
- -
LT Finance Leases
- -
344
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
192
192
192
Market Capitalization
28,506
18,619
25,622

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
12,365
- -
Cash, Cash Equivalents & STI
- -
1,118
- -
Accounts Receivable, Net
- -
3,730
- -
Inventories
- -
5,037
- -
Total Current Liabilities
- -
9,744
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,831
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.21%
7.1%
14.41%
Free Cash Flow
-187.56%
-160.4%
-225.97%
Net Income, GAAP
480.99%
-68.61%
-119.87%
Sales/Revenue/Turnover
14.02%
8.64%
7.1%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3,809
4,173
4,310
4,316
15,978
2026
4,077
4,598
4,572
4,248
17,112
2027
5,199
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-1.99
-5.89
-0.24
-0.04
-8.03
2026
-0.53
-0.77
-1.91
4.59
1.46
2027
-1.65
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Ashish Subhash Dandekar
Full Time Employees
1,557
Sector
Process industries
Industry
Chemicals: specialty
Address
In G.S. Point Mumbai MA India 400098
IPO Date
Jan 20, 2015
Business
Camlin Fine Sciences Limited manufactures specialty chemicals focused on shelf-life extension solutions, aroma ingredients, and performance chemicals for industries including food and beverages, pet food and rendering, animal nutrition, petrochemicals, biofuels, flavors and fragrances, pharmaceuticals, agrochemicals, dyes and pigments, and polymers. The company produces traditional antioxidants such as TBHQ, BHA, BHT, and Ascorbyl Palmitate; natural alternatives like NaSure rosemary extract, green tea, and mixed tocopherols under brands Xtendra and NaSure; aroma ingredients including adorr vanillin, ethyl vanillin, floral boosters, Intense Green, and Vetigreen; performance chemicals such as hydroquinone, catechol, guaiacol, veratrole, hydroquinone monomethyl ether (MEHQ), and 4-tert-butylcatechol under the Dinamic brand; and nutritional products like Biosus vegan DHA and Ezential functional ingredients. Founded in 1993 as part of Camlin Ltd. with fine chemicals operations starting in 1984 and demerged into an independent entity in 2006, Camlin Fine Sciences is headquartered in Mumbai, India, and operates manufacturing facilities and subsidiaries across India, Italy, Brazil, Mexico, the United States, China, Singapore, Belgium, France, Chile, Colombia, Peru, Guatemala, Dominican Republic, and Cuba, serving a global sales network in over 160 locations with more than 1,000 employees and annual turnover exceeding USD 200 million. Recent developments include the completion in November 2025 of its acquisition of a 78.68% majority stake in French firm Vinpai S.A. through allotment of over 41 lakh equity shares valued at more than INR 101 crore, enhancing natural ingredient capabilities including algae-based solutions; full acquisition of the remaining stake in Mexican subsidiary Dresen Quimica in late 2024 via USD 11 million funding; and ongoing expansions such as the adorr vanillin facility in Dahej, India, alongside participation in global events like Pet Food Forum and Fi India in 2025.